Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunction in rats with chronic renal failure

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 3, 2007, Pages 131-139

  Yamamizu, Kohei ^a,b   Shinozaki, Kazuya ^a   Ayajiki, Kazuhide ^a   Gemba, Munekazu ^b   Okamura, Tomio ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

5, 6, 7, 8 tetrahydrobiopterin; Chronic renal failure; Endogenous NOS inhibitors; Endothelial dysfunction; Nitric oxide; Superoxide anion

Indexed keywords

ARGININE; CALCIMYCIN; DIMETHYLARGININASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BIOACCUMULATION; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; IN VITRO STUDY; IN VIVO STUDY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANIMALS; AORTA; ARGININE; BIOPTERIN; BLOOD PRESSURE; CALCIMYCIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; KIDNEY FAILURE, CHRONIC; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 34147195459     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802f9923     Document Type: Article

References (49)

1. Levin A, Stevens L, McCullough PA. Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. Postgrad Med. 2002;111:53-60.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S112-S119.
3. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-12.
4. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med. 1993;328:628-635.
5. Stamler J, Mendelsohn ME, Amarante P, et al. N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res. 1989;65:789-795.
6. Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis. 1997;129:261-269.
7. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
8. Jourd'heuil D, Jourd'heuil FL, Kutchukian PS, et al. Reaction of superoxide and nitric oxide with peroxynitrite. Implications for peroxynitrite-mediated oxidation reactions in vivo. J Biol Chem. 2001;276:28799-28805.
9. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424-C1437.
10. Matsuoka H, Itoh S, Kimoto M, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 1997;29:242-247.
11. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
12. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol. 1995;269:C750-C756.
13. Closs EI, Basha FZ, Habermeier A, et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997;1:65-73.
14. Tojo A, Welch WJ, Bremer V, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52:1593-1601.
15. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970;245:5751-5758.
16. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594-600.
17. Creager MA, Gallagher SJ, Girerd XJ, et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
18. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol. 1997;29:479-485.
19. Theilmeier G, Chan JR, Zalpour C, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol. 1997;17:3557-3564.
20. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
21. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
22. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a highfat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20:2039-2044.
23. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987-992.
24. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol. 2001;281:H981-H986.
25. Reif A, Frohlich LG, Kotsonis P, et al. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem. 1999;274:24921-24929.
26. Shinozaki K, Kashiwagi A, Masada M, et al. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord. 2004;4:1-11.
27. ·- imbalance in insulin-resistant rat aorta. Diabetes. 1999;48:2437-2445.
28. Hong HJ, Hsiao G, Cheng TH, et al. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension. 2001;38:1044-1048.
29. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
30. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
31. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000;87:566-573.
32. Tiefenbacher CP, Bleeke T, Vahl C, et al. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation. 2000;102:2172-2179.
33. Yamashiro S, Noguchi K, Kuniyoshi Y, et al. Role of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Cardiovasc Surg (Torino). 2003;44:37-49.
34. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93.
35. Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612-619.
36. G-nitro-L-arginine in isolated dog and monkey cerebral arteries. Stroke. 1993;24:1584-1588.
37. Teerlink T, Nijveldt RJ, de Jong S, et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303:131-137.
38. Osicka TM, Hankin AR, Comper WD. Puromycin aminonucleoside nephrosis results in a marked increase in fractional clearance of albumin. Am J Physiol. 1999;277:F139-F145.
39. Yokozawa T, Zheng PD, Oura H, et al. Animal model of adenine-induced chronic renal failure in rats. Nephron. 1986;44:230-234.
40. Horiba N, Masuda S, Takeuchi A, et al. Gene expression variance based on random sequencing in rat remnant kidney. Kidney Int. 2004;66:29-45.
41. Ashab I, Peer G, Blum M, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995;47:1515-1521.
42. Podjarny E, Hasdan G, Bernheim J, et al. Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats. Nephrol Dial Transplant. 2004;19:2223-2227.
43. Cross JM, Donald AE, Kharbanda R, et al. Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure. Kidney Int. 2001;60:2318-2323.
44. Lockette W, Otsuka Y, Carretero O. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension. 1986;8:II61-II66.
45. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023-1030.
46. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem. 1989;264:10205-10209.
47. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003;4:41-51.
48. Fleck C, Janz A, Schweitzer F, et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl. 2001;78:S14-S18.
49. Shinozaki K, Nishio Y, Yoshida Y, et al. Supplement of tetrahydrobiopterin by a gene transfer of GTP cyclohydrolase I cDNA improves vascular dysfunction in insulin-resistant rats. J Cardiovasc Pharmacol. 2005;46:505-512.